Farxiga vs Metformin Side-Effect Profile: Head-to-Head

How Each Drug Works

Knowing the mechanism makes the side-effect list predictable rather than mysterious.

Metformin: Suppressing Hepatic Glucose

Metformin activates AMP-activated protein kinase (AMPK), reducing hepatic gluconeogenesis by roughly 30% and improving peripheral insulin sensitivity [1]. Because it does not stimulate insulin secretion, it cannot drop blood sugar below the body's own regulatory floor. That single fact explains the near-zero monotherapy hypoglycemia rate seen in UKPDS 34 [2].

The drug is absorbed in the small intestine. High luminal drug concentrations irritate enterocytes, slow GI motility, and alter the gut microbiome, all of which contribute to nausea and diarrhea. Extended-release (ER) formulations reduce peak luminal concentrations and cut GI discontinuation rates by approximately half compared to immediate-release [3].

Farxiga: Blocking Renal Glucose Reabsorption

Dapagliflozin binds the sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule. Normally, SGLT2 reclaims nearly all filtered glucose. Farxiga blocks roughly 50% of that reabsorption, excreting 60-80 grams of glucose per day in urine [4]. The glycosuric effect is the source of both its benefits and its characteristic risks: the glucose-rich urinary environment promotes yeast and bacterial overgrowth, while volume depletion from osmotic diuresis can drop blood pressure and, in certain patients, provoke acute kidney injury.

Side-Effect Profiles: A System-by-System Breakdown

Gastrointestinal Tract

Metformin is the more troublesome drug for the gut. Across pooled data from registration trials, nausea occurs in 10-25% of patients, diarrhea in 10-53%, and vomiting in 6-7% [3]. Symptoms typically emerge within the first 2-4 weeks and often resolve by week 8, but roughly 5% of patients stop the drug permanently due to GI intolerance.

Farxiga's GI burden is low. In the DECLARE-TIMI 58 trial (N=17,160), nausea and diarrhea rates were not statistically different from placebo [5]. Patients switching from metformin to Farxiga frequently report a noticeable improvement in GI comfort within days.

The clinical takeaway: if GI tolerability is the primary concern, Farxiga has a clear advantage.

Genitourinary Tract

This is where Farxiga's profile diverges most sharply from metformin's.

Genital mycotic infections occur in approximately 8.4% of women and 3.1% of men treated with dapagliflozin, compared to 2.3% and 0.9% respectively with placebo [4]. Most infections are mild, respond to standard antifungal therapy, and do not require drug discontinuation. Patients with recurrent vulvovaginal candidiasis, uncircumcised men, or those with poor genital hygiene face higher baseline risk.

Urinary tract infections (UTIs) were initially a theoretical concern given glycosuria, but large trial data are reassuring. In DECLARE-TIMI 58, UTI rates with dapagliflozin were similar to placebo (8.0% vs 8.1%) [5]. Metformin carries no meaningful genitourinary risk.

Hypoglycemia

Neither drug causes hypoglycemia as monotherapy. That shared characteristic makes both appropriate as first-line choices for patients with type 2 diabetes (T2D) who have not yet started insulin or a sulfonylurea.

The risk rises when either drug is combined with insulin or sulfonylureas. In that setting, dose adjustments of the insulin or sulfonylurea may be necessary, particularly with Farxiga, whose glycosuria adds an additive glucose-lowering effect to secretagogue-driven insulin release.

Volume Status and Blood Pressure

Farxiga produces mild osmotic diuresis, reducing systolic blood pressure by approximately 3-4 mmHg on average [4]. That effect is beneficial in hypertensive patients with T2D but can cause symptomatic hypotension in elderly patients on loop diuretics or those who are volume-depleted. The FDA label for dapagliflozin advises assessing volume status before initiation and correcting dehydration first [4].

Metformin has no meaningful effect on blood pressure or volume status.

Renal Function

Metformin does not harm the kidney directly, but impaired kidneys cannot clear the drug adequately, allowing plasma concentrations to rise and increasing lactic acid accumulation. Current ADA guidance restricts metformin use at eGFR <30 mL/min/1.73m² and recommends caution between eGFR 30-44 [6].

Farxiga's glycemic effect depends on functioning nephrons. Below eGFR 45, glucose excretion falls substantially and HbA1c-lowering becomes modest. However, the 2023 DAPA-CKD data demonstrated that the cardio-renal protective benefit of dapagliflozin extends to eGFR as low as 25 mL/min/1.73m², independent of diabetes status [7]. The FDA approved Farxiga for CKD on that basis. This creates a scenario where a patient may be prescribed Farxiga at an eGFR that excludes metformin, not primarily for glucose control but for kidney and heart protection.

Lactic Acidosis

Lactic acidosis is the most feared metformin complication. The incidence is low, estimated at 3-10 cases per 100,000 patient-years in modern cohorts that exclude patients with significant renal or hepatic impairment [3]. Risk factors include eGFR <30, acute illness with dehydration, excessive alcohol use, and hepatic failure. Lactic acidosis is not a recognized risk with dapagliflozin.

Diabetic Ketoacidosis

Euglycemic diabetic ketoacidosis (DKA) is a class-wide concern for SGLT2 inhibitors. With dapagliflozin, DKA can occur even when plasma glucose is below 250 mg/dL, making it easy to miss. Reported incidence in post-marketing data is approximately 0.5-1 per 1,000 patient-years [8]. Precipitating factors include prolonged fasting, very low-carbohydrate diets, surgical procedures, heavy alcohol intake, and insulin dose reduction. The FDA added a boxed warning for SGLT2 inhibitor-associated DKA in 2015 [8].

Metformin does not cause DKA.

Fournier's Gangrene

The FDA issued a safety communication in 2018 noting cases of Fournier's gangrene (necrotizing fasciitis of the perineum) with SGLT2 inhibitors, including dapagliflozin [8]. The absolute risk is very low, fewer than 20 cases were identified in the first 5 years of SGLT2 inhibitor use across millions of prescriptions, but the condition is life-threatening and warrants patient education about perineal pain, swelling, or erythema.

Metformin has no associated risk of Fournier's gangrene.

Bone and Amputation Risk

Early data with canagliflozin (a different SGLT2 inhibitor) raised concerns about lower-limb amputations. DECLARE-TIMI 58, which studied dapagliflozin specifically, found no statistically significant increase in amputation risk compared to placebo (1.4% vs 1.3%, P<0.001 not met for difference) [5]. Bone fracture risk was also similar between groups. Metformin has no established effect on amputation or fracture risk.

Vitamin B12 Deficiency

Long-term metformin use reduces vitamin B12 absorption by competing with the calcium-dependent ileal absorption mechanism. After 10 years of metformin therapy in UKPDS follow-up, approximately 7% of patients showed clinically significant B12 deficiency [2]. Peripheral neuropathy that appears or worsens in a patient on long-term metformin should prompt B12 measurement. Annual B12 monitoring is reasonable after 4 years of use.

Farxiga has no effect on B12 levels.

Cardiovascular and Organ-Protective Outcomes

Side-effect profiles do not exist in isolation from benefit profiles. A drug's risk is only meaningful in relation to what it prevents.

DAPA-HF: Farxiga's Heart Failure Signal

DAPA-HF (N=4,744) randomized patients with heart failure with reduced ejection fraction (HFrEF) to dapagliflozin 10 mg or placebo on top of standard therapy. At a median follow-up of 18.2 months, dapagliflozin reduced the composite of worsening heart failure or cardiovascular death by 26% (hazard ratio 0.74; 95% CI 0.65-0.85; P<0.001) [1]. This benefit extended to patients without diabetes. No comparable benefit has been demonstrated for metformin in patients with established HFrEF.

UKPDS 34: Metformin's Foundational Evidence

UKPDS 34 (N=1,704 overweight patients with newly diagnosed T2D) compared intensive glucose control with metformin to conventional therapy. Over a median of 10.7 years, metformin reduced any diabetes-related endpoint by 32%, diabetes-related death by 42%, and all-cause mortality by 36% compared to conventional therapy [2]. These benefits exceeded those seen with sulfonylurea or insulin in the same trial, suggesting a mechanism beyond glucose control alone, possibly cardiovascular or anti-inflammatory.

ADA 2024 Guideline Positioning

The American Diabetes Association's 2024 Standards of Care state: "In patients with type 2 diabetes and established cardiovascular disease, heart failure, or chronic kidney disease, SGLT2 inhibitors should be considered independent of HbA1c or individualized HbA1c target" [6]. Metformin remains recommended as initial therapy for most patients with T2D who tolerate it, particularly when cost is a concern.

The decision between these two drugs is therefore rarely purely about side effects. A prescriber choosing between them should map the patient's primary risk domains. The framework below organizes that decision:

Prioritize Farxiga when: the patient has HFrEF, CKD with eGFR 25-60, established atherosclerotic cardiovascular disease, or cannot tolerate metformin GI side effects.

Prioritize Metformin when: the patient has no established cardiovascular or renal disease, cost is a barrier, or the provider wants a drug with 20-plus years of real-world safety data.

Consider both together when: the patient needs additive HbA1c reduction and has no contraindication to either agent. The combination is rational because the mechanisms do not overlap, and the side-effect profiles are largely non-additive.

Practical Prescribing Considerations

Starting Doses and Titration

Metformin is typically started at 500 mg once daily with the evening meal and titrated by 500 mg per week to a target of 1,500-2,000 mg per day in divided doses. The ER formulation, taken once daily with dinner, achieves similar HbA1c reduction with meaningfully fewer GI complaints.

Farxiga is started at 10 mg once daily in the morning. No titration is required for glycemic indication. For heart failure, the approved dose is also 10 mg once daily, the same as for T2D.

Drug Interactions

Metformin interacts with iodinated contrast media. Current ADA guidance recommends holding metformin at the time of contrast administration in patients with eGFR <60 and restarting 48 hours later once renal function is confirmed stable [6].

Farxiga's interactions are fewer. Volume depletion from co-administered loop diuretics or ACE inhibitors deserves attention given the drug's diuretic effect. Insulin dose reduction by 15-20% at Farxiga initiation is advisable to avoid hypoglycemia.

Perioperative Management

Both drugs require specific perioperative handling. Metformin should be held on the day of surgery and for 48 hours post-procedure if significant contrast exposure or acute kidney injury is anticipated. Farxiga carries the DKA risk and should be held for a minimum of 3 days before elective surgery per most anesthesiology society guidance, given the risk of euglycemic DKA in the fasted surgical patient [8].

Monitoring Parameters

For metformin: check eGFR at baseline, annually, and with any acute illness. Check B12 after 4 years of continuous use. No routine liver function testing is required.

For Farxiga: check eGFR at baseline. Monitor signs of volume depletion in elderly or diuretic-treated patients. Educate patients to report perineal pain, polyuria beyond expected levels, or vomiting with fatigue (potential DKA signs).

Who Should Not Take Each Drug

Metformin is contraindicated in eGFR <30 mL/min/1.73m², active hepatic disease with elevated transaminases greater than 3 times the upper limit of normal, acute or chronic metabolic acidosis including DKA, and known hypersensitivity to the drug.

Farxiga is contraindicated in eGFR <15 (for CKD indication, down to 25), dialysis dependence for its glycemic indication, and in patients with type 1 diabetes outside a supervised clinical trial given DKA risk. The drug is not recommended in pregnancy; animal data show fetal renal toxicity in the second and third trimesters [8].

Weight and Metabolic Effects

Both drugs produce modest weight loss, but through different mechanisms and to different degrees.

Metformin reduces appetite slightly, possibly through GLP-1 pathway modulation, and produces an average weight loss of 1-3 kg over 6-12 months in most patients [3].

Farxiga's weight reduction averages 2-3 kg at 26 weeks and reaches 3-4 kg by 52 weeks in dedicated weight studies, driven almost entirely by caloric loss through glycosuria [4]. The effect is somewhat self-limiting: as glycosuria reduces blood glucose, the filtered glucose load also falls, blunting further loss. Neither drug approaches the weight-loss magnitude seen with GLP-1 receptor agonists such as semaglutide (14.9% body weight reduction over 68 weeks in STEP-1, N=1,961) [9].

Cost and Access

Generic metformin costs under $10 per month at most U.S. Pharmacies, making it one of the most accessible glucose-lowering agents available. The American Diabetes Association explicitly cites cost as a reason to prefer metformin as initial therapy in patients without compelling cardiovascular or renal indications for another class [6].

Farxiga carries a retail price of approximately $500-600 per month without insurance. Most commercial insurance plans cover it with prior authorization when the patient meets criteria (established T2D, HFrEF, or CKD). Manufacturer copay programs can reduce out-of-pocket costs to under $10/month for eligible commercially insured patients, but these programs do not apply to Medicare or Medicaid beneficiaries. Access remains a real barrier.